Stress-induced aldosterone hyper-secretion in a substantial subset of patients with essential hypertension

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 8, 2015, Pages 2857-2864

  Markou, Athina ^a   Sertedaki, Amalia ^b   Kaltsas, Gregory ^b   Androulakis, Ioannis I ^a   Marakaki, Chrisanthi ^a   Pappa, Theodora ^a   Gouli, Aggeliki ^a   Papanastasiou, Labrini ^a   Fountoulakis, Stelios ^a   Zacharoulis, Achilles ^a   Karavidas, Apostolos ^a   Ragkou, Despoina ^a   Charmandari, Evangelia ^b   Chrousos, George P ^b   Piaditis, George P ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CORTICOTROPIN; EPLERENONE; HYDROCORTISONE; RENIN; SPIRONOLACTONE; ALDOSTERONE SYNTHASE; CHIMERIC PROTEIN; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; KCNJ5 PROTEIN, HUMAN; STEROID 11BETA MONOOXYGENASE;

ADULT; ALDOSTERONE TO RENIN RATIO; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CHIMERA; CHRONIC STRESS; CONTROLLED STUDY; CYP11B1 GENE; CYP11B2 GENE; DIASTOLIC BLOOD PRESSURE; DNA SCREENING; ESSENTIAL HYPERTENSION; GENE; GENE MUTATION; GENE SEQUENCE; HORMONE RELEASE; HUMAN; KCNJ5 GENE; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREADMILL TEST; WAIST CIRCUMFERENCE; ADENOMA; ADRENAL TUMOR; BLOOD; CASE CONTROL STUDY; COMPLICATION; GENETICS; HYPERALDOSTERONISM; HYPERTENSION; MENTAL STRESS; METABOLISM; SECRETION (PROCESS);

ADENOMA; ADRENAL GLAND NEOPLASMS; ADRENOCORTICOTROPIC HORMONE; ALDOSTERONE; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP11B2; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; HUMANS; HYDROCORTISONE; HYPERALDOSTERONISM; HYPERTENSION; MIDDLE AGED; MUTANT CHIMERIC PROTEINS; RENIN; STEROID 11-BETA-HYDROXYLASE; STRESS, PSYCHOLOGICAL;

EID: 84939198118     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1268     Document Type: Article

References (28)

1. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93:3266-3281.
2. Douma S, Petidis K, Doumas M, et al. Prevalence of primary hyperaldosteronism in resistant hypertension: A retrospective observational study. Lancet. 2008;371:1921-1926.
3. Gouli A, Kaltsas G, Tzonou A, et al. High prevalence of autonomous aldosterone secretion among patients with essential hypertension. Eur J Clin Invest. 2011;41:1227-1236.
4. Markou A, Pappa T, Kaltsas G, et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: A very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab. 2013;98:1409-1416.
5. Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: Cardiovascular, renal and metabolic implications. Trends Endocrinol Metab. 2008;19:88-90.
6. Rayfield EJ, Rose LI, Dluhy RG, Williams GH. Aldosterone secretory and glucocorticoid excretory responses to alpha 1-24 ACTH (Cortrosyn) in sodium-depleted normal man. J Clin Endocinol Metab. 1973;36:30-35.
7. Lifton RP, Dluhy RG, Powers M, et al. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 1992;2:66-74.
8. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab. 2000;85:2160-2166.
9. Mulatero P, Tizzani D, Viola A, et al. Prevalence and characteristics of familial hyperaldosteronism: The PATOGEN study (primary aldosteronism in Torino-GENetic forms). Hypertension. 2011;58: 797-803.
10. + channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768-772.
11. Charmandari E, Sertedaki A, Kino T, et al. A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension. J Clin Endocrinol Metab. 2012;97:E1532-E1539.
12. Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat Rev Endocrinol. 2013;9:104-112.
13. Scholl UI, Nelson-Williams C, Yue P, et al. Hypertension with or without adrenal hyperplasia due to different inherited mutations in the potassium channel KCNJ5. Proc Natl Acad Sci U S A. 2012; 109:2533-2538.
14. Mulatero P, Tauber P, Zennaro MC, et al. KCNJ5 mutations in European families with nonglucocorticoid remediable familial hyperaldosteronism. Hypertension. 2012;59:235-240.
15. Xekouki P, Hatch MM, Lin L, et al. KCNJ5 mutations in the National Institutes of Health cohort of patients with primary hyperaldosteronism: An infrequent genetic cause of Conn's syndrome. Endocr Relat Cancer. 2012;19:255-260.
16. McManus RJ, Caulfield M, Williams B. NICE hypertension guideline 2011: Evidence-based evolution. Br Med J. 2012;344:e181.
17. Arvat E, Di Vito L, Lanfranco F, et al. Stimulatory effect of adrenocorticotropin on cortisol, aldosterone, and dehydroepiandrosterone secretion in normal humans: dose-response study. J Clin Endocrinol Metab. 2000;85:3141-3146.
18. Bruce RA, Blackmon JR, Jones JW, Strait G. Exercising testing in adult normal subjects and cardiac patients. Paediatrics. 1963;32: 742-756.
19. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun. 1995; 207:565-571.
20. Kojima I, Kojima K, Rasmussen H. Role of calcium and Camp in the action of adrenocorticotropin on aldosterone secretion. J Biol Chem. 1985;260:4248-4256.
21. Spät A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84: 489-539.
22. Foster RH. Reciprocal influences between the signalling pathways regulating proliferation and steroidogenesis in adrenal glomerulosa cells. J Mol Endocr. 2004;32:893-902.
23. Lin L, Hindmarsh PC, Metherell LA, et al. Severe loss-of-function mutations in the adrenocorticotropinreceptor (ACTR, MC2R) can be found in patients diagnosed with salt-losing adrenal hypoplasia. Clin Endocrinol. 2007;66:205-210.
24. Luger A, Deuster PA, Kyle SB, et al. Acute hypothalamic-pituitary-adrenal responses to the stress of treadmill exercise. Physiologic adaptations to physical training. N Engl J Med. 21. 1987;316:1309-1315.
25. Luger A, Deuster PA, Debolt JE, Loriaux DL, Chrousos GP. Acute exercise stimulates the renin-angiotensin-aldosterone axis: Adaptive changes in runners. Horm Res. 1988;30:5-9.
26. Deuster PA, Chrousos GP, Luger A, et al. Hormonal and metabolic responses of untrained, moderately trained, and highly trained men to three exercise intensities. Metabolism. 1989;38(2):141-148.
27. Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab. 2004; 89:2736-2740.
28. Papanastasiou L, Markou A, Pappa T, et al. Primary aldosteronism in hypertensive patients: Clinical implications and target therapy. Eur J Clin Invest. 2014;44:697-706.